Pharmacological characterization of the late phase reduction in lung functionsand correlations with microvascular leakage and lung edema inallergen-challenged Brown Norway rats

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 677-684

  Mauser, Peter J ^a   House, Aileen ^a   Jones, Howard ^a   Correll, Craig ^a   Boyce, Christopher ^a   Chapman, Richard W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brown Norway rats; Forced expiratory maneuvers; Inflammation; Mediators of inflammation; Pulmonary edema

Indexed keywords

7 TM; 7TM; ALLERGEN; BETAMETHASONE; INDOMETACIN; LIPOXYGENASE; MEPYRAMINE; METHYSERGIDE; MK 7246; MONTELUKAST; OVALBUMIN; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; BROWN NORWAY RAT; CONTROLLED STUDY; CORRELATION ANALYSIS; FORCED VITAL CAPACITY; LUNG DISEASE; LUNG EDEMA; LUNG FUNCTION; LUNG MICROVASCULAR LEAKAGE; LUNG WEIGHT; MALE; MAST CELL; NONHUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RAT; SENSITIZATION;

BROWN NORWAY RATS; FORCED EXPIRATORY MANEUVERS; INFLAMMATION; MEDIATORS OF INFLAMMATION; PULMONARY EDEMA;

ALLERGENS; ANIMALS; ARACHIDONIC ACID; ASTHMA; BETAMETHASONE; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; INFLAMMATION; LIPOXYGENASE; MALE; MICROVESSELS; OVALBUMIN; PEAK EXPIRATORY FLOW RATE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PULMONARY EDEMA; RATS; RATS, INBRED BN; VITAL CAPACITY;

EID: 84887994060     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.005     Document Type: Article

References (36)

1. Paredi P., Barnes P.J. The airway vasculature: recent advances and clinical implications. Thorax 2009, 64:444-456.
2. Flick M.R. Pulmonary edema and acute lung injury. Textbook of respiratory medicine 1988, 1354-1409. WB Saunders Co, Philadelphia. J.F. Murray, J.A. Nadel (Eds.).
3. Brown R.H., Zerhouni E.A., Mitzner W. Airway edema potentiates airway reactivity. JAppl Physiol 1995, 1242-1248.
4. Hele D.J., Birrell M.A., Webber S.E., Foster M.L., Belvisi M.G. Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 2001, 132:481-488.
5. Carreño C., Domènech A., Prats N., Miralpeix M., Ramis I. Characterization of a model of tracheal plasma extravasation in passively sensitized rats using anti-allergic and anti-inflammatory drugs by oral and intratracheal route. Pharmacol Ther 2012, 25:87-93.
6. Olivenstein R., Du t, Xu L.J., Martin J.G. Microvascular leakage in the airway wall and lumen during allergen challenge induced early and late responses in rats. Pulm Pharmacol Ther 1997, 10:223-230.
7. Tigani B., Cannet C., Karmouty-Quintana H., Blé F.-X., Zurbruegg S., Schaeublin E., et al. Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI. Am J Physiol Lung Cell Mol Physiol 2007, 292:L644-L653.
8. 4 integrin in antigen-induced changes in microvascular permeability associated with lung inflammation in sensitized Brown Norway rats. Am J Respir Cell Mol Biol 1997, 17:757-766.
9. Celly C.S., House A., Sehring S.J., Zhang X.Y., Jones H., Hey J.A., et al. Temporal profile of forced expiratory lung function in allergen-challenged Brown-Norway rats. Eur J Pharmacol 2006, 540:147-154.
10. Chapman R.W., Curran A.K., House A., Richard J., Salisbury B., Hunter J.C., et al. Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats. Pulm Pharmacol Ther 2011, 24:67-73.
11. Tigani B., Cannet C., Zurbruegg S., Schaeublin E., Mazzoni L., Fozard J.R., et al. Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed non-invasively by magnetic resonance imaging. Br J Pharmacol 2003, 140:239-246.
12. Albert D.H., Malo P.E., Tapang P., Shaughnessy T.K., Morgan D.W., Wegner C.D., et al. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. JPharmacol Exp Ther 1998, 284:83-88.
13. Karmouty-Quintana H., Blé F.-X., Cannet C., Zurbruegg S., Fozard J.R., Page C.P., et al. Invivo pharmacological evaluation of compound 48/80-induced airways oedema by MRI. Br J Pharmacol 2008, 154:1063-1072.
14. Hammerbeck D.M., McGurran S.M., Radziszewski P.L., Egging E.A., Johnson D.D., Hupperts A.M., et al. Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. Inflammation 2000, 24:317-329.
15. Gervais F.G., Sawyer N., Stocco R., Hamel M., Krawczyk C., Sillaots S., et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol 2011, 79:69-76.
16. Gallant M., Beaulieu C., Berthelette C., Colucci J., Crackower M.A., Dalton C., et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett 2011, 21:288-293.
17. Molinaro C., Bulger P.G., Lee E.E., Kosjek B., Lau S., Gauvreau D., et al. CRTH2 antagonist MK-7246: a synthetic evolution from discovery through development. JOrg Chem 2012, 77:2299-2309.
18. Ulven T., Receveur J.-M., Grimstrup M., Rist Ø., Frimurer M., Gerlach L.-O., et al. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. JMed Chem 2006, 49:6638-6641.
19. Baluk P., McDonald D.M. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol Lung Cell Mol Physiol 1994, 266:L461-L468.
20. Parker J.C., Townsley M.I. Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L231-L246.
21. 3-receptors inhibit sympathetic modulation of airway microvascular leakage in guinea pigs. Eur J Pharmacol 1994, 254:283-286.
22. Beckmann N., Tigani B., Mazzoni L., Fozard J.R. Magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs. Trends Pharmacol Sci 2003, 24:550-554.
23. 4. JAppl Physiol 1996, 80:583-590.
24. Farmer J.B., Richards I.M., Sheard P., Woods A.M. Mediators of passive lung anaphylaxis in the rat. Br J Pharmacol 1975, 55:57-64.
25. 2 receptor. JPharmacol Exp Ther 2005, 312:954-960.
26. Brange C., Smailagic A., Jansson A.H., Middleton B., Miller-Larsson A., Taylor J.D., et al. Sensitivity of disease parameters to flexible budesonide/formoterol treatment in an allergic rat model. Pulm Pharmacol Ther 2009, 22:20-26.
27. Anthes J.C., McLeod R.L., Chapman R.W., Jia Y., House A., Fernandez X., et al. Changes in upper and lower airway inflammation following administration of mometasone furoate in allergen-challenged Brown Norway rats. ArzneimForsch 2009, 59:13-20.
28. 2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. JPharmacol Exp Ther 2005, 313:64-69.
29. Ihaku D., Cameron L., Suzuki M., Molet S., Martin J., Hamid Q. Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, eosinophilia, and IL-5-expressing cells in Brown Norway rats. JAllergy Clin Immunol 1999, 104:1147-1154.
30. Hallstrand T.S., Henderson W.R. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010, 10:60-66.
31. 2 in the pathogenesis of asthma. Curr Mol Med 2008, 8:365-375.
32. Pettipher R. The roles of the prostaglandin D(2) receptor DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008, 153(Suppl. 1):S191-S199.
33. Rist Ø., Grimstrup M., Receveur J.-M., Frimurer T.M., Ulven T., Kostenis E., et al. Novel selective thiazoleacetic acids as CRTH2 anatgonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett 2010, 20:1177-1180.
34. Lima C., Souza V.M.O., Soares A.L., Macedo M.S., Tavares-de-Lima W., Vargaftig B.B. Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with airway chronic allergic inflammation and remodeling in a murine model of asthma. Clin Exp Allergy 2007, 37:723-734.
35. Weigand L.A., Myers A.C., Meeker S., Undem B.J. Mast cell-cholinergic nerve interaction in mouse airways. JPhysiol 2009, 587:3355-3362.
36. 4 receptors in the peripheral rat lung. Eur J Pharmacol 2013, 699:141-149.